Pyxis Oncology, Inc. Common Stock (PYXS) Stock
NASDAQ · PYXS
2.80
Fundamentals
Market cap
$238.55M
Price / Earnings ratio
-2.7x
Price / Sales ratio
22.1x
Price / Book ratio
21.3x
Return on assets
-85.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

InvestorPlace
3 Biotech Stocks to Buy on the Dip: March 2024
NeutralPYXSMarch 27, 2024
InvestorPlaceNeutral
3 Biotech Stocks to Buy on the Dip: March 2024
PYXS

InvestorPlace
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
NeutralPYXSMarch 19, 2024
InvestorPlaceNeutral
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
PYXS

PennyStocks
Why Am I Losing Money With Penny Stocks? 3 Reasons
NeutralPYXSMarch 29, 2023
PennyStocksNeutral
Why Am I Losing Money With Penny Stocks? 3 Reasons
PYXS
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy4
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
17M11M5M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
110M72M36M0
Revenue to Profit
2025$13.9M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-79.6M
Net incomeEarnings
No data available
% positive news of 3 articles
published over the past 14 days
Latest news

InvestorPlace
3 Biotech Stocks to Buy on the Dip: March 2024
NeutralPYXSMarch 27, 2024
InvestorPlaceNeutral
3 Biotech Stocks to Buy on the Dip: March 2024
PYXS

InvestorPlace
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
NeutralPYXSMarch 19, 2024
InvestorPlaceNeutral
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
PYXS

PennyStocks
Why Am I Losing Money With Penny Stocks? 3 Reasons
NeutralPYXSMarch 29, 2023
PennyStocksNeutral
Why Am I Losing Money With Penny Stocks? 3 Reasons
PYXS
About Pyxis Oncology, Inc. Common Stock
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
SectorHealthcare
IndustryBiotechnology
Employees56
CEOMr. Thomas Civik
IPO DateOct 6, 2021
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas Civik | Interim CEO & Director | 1969 |
| Mr. Jitendra Wadhane C.A., CPA | Chief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer | 1981 |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer | — |
| Donna Regalado | Head of Human Resources | — |
| Dr. Charles T. Gombar Ph.D. | Senior Vice President of Portfolio & Program Management | — |
| Dr. Michael Bui | Senior Vice President of Global Regulatory Affairs | — |
| Dr. Supriya Roth Ph.D. | Head of Commercial Development | — |
| Dr. Shui He Ph.D. | Head of Biometrics | — |
| Dr. Hongwei Wang M.D., Ph.D. | Head of ADC Development & Clinical Strategy | — |
| Dr. Marsha Crochiere Ph.D. | Head of Translational Medicine & Research | — |
Fundamentals
Valuation
Market cap$238.55M
Price-to-sales ratio22.07
Price-to-book value21.29
Price-earnings ratio-2.70
Return on Equity-136.00%
Return on Sales-580.00%
Return on Assets-85.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.41
Income Statement
Average volume881,374
EBITDA$-75.07M
1 year high (52w)$5.55
1 year low (52w)$1.03
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
4 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$10.50
Est return
275.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.1 | -3.3 | -10.7 | |||||||||
| 2022 | -16.5 | -36.2 | -22.8 | -31.4 | -3.1 | -0.4 | +8.6 | +0.0 | -25.1 | -6.5 | -14.2 | -7.6 |
| 2023 | +13.0 | +39.3 | +65.7 | -27.5 | +11.4 | -22.7 | -2.6 | -15.2 | -14.2 | -18.5 | -8.1 | +10.4 |
| 2024 | +85.0 | +71.4 | -35.4 | -7.1 | -15.0 | -12.0 | +22.5 | +2.7 | +6.7 | +1.4 | -46.5 | -22.0 |
| 2025 | -7.1 | -20.7 | -11.7 | +19.6 | +10.0 | -9.8 | +3.7 | +16.4 | +66.9 | +62.6 | +36.2 | -73.8 |
| 2026 | +26.1 | -3.9 | -0.7 | +15.6 | +4.7 | +68.2 | -7.0 | +6.6 | -16.9 |



